In what some scientists are calling a ‘defining moment’ for dementia research, results from trials of Donanemab found it significantly delayed the worsening of symptoms in people with certain types of dementia.
This is now the second drug — Lecanemba was approved recently — aimed at slowing the decline in Alzheimer’s disease.
If, as scientists believe, Donanemab can slow early Alzheimer’s by up to 60%, then this is indeed a game changer.
While there is no cure for Alzheimer’s (yet), the new drugs will prevent the disease from getting worse. They won’t improve patients’ memories or cognitive abilities. What Leqembi can do is modestly slow down cognitive decline in patients who are in the early stages of the disease.
Data from a large clinical trial suggested that the drug may slow decline by about five months over a period of 18 months for those patients